Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer

BACKGROUND: The clinical benefit of a selective cyclooxygenase-2 inhibitor, celecoxib, combined with anticancer therapy in advanced non-small-cell lung cancer (NSCLC) remains unclear. A meta-analysis was performed to address the efficacy and safety of celecoxib in patients with advanced NSCLC. MATER...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Lilan, Zhang, Wei, Zhang, Hongman, Shen, Jie, Zou, Jingwen, Luo, Peng, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086108/
https://www.ncbi.nlm.nih.gov/pubmed/30122902
http://dx.doi.org/10.2147/DDDT.S169627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086108/
https://www.ncbi.nlm.nih.gov/pubmed/30122902
http://dx.doi.org/10.2147/DDDT.S169627

Ejemplares similares